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Abstract
Background: In a quest for a needle-free vaccine administration strategy, we evaluated the ocular conjunctiva as an
alternative mucosal immunization route by profiling and comparing the local and systemic immune responses to the
subcutaneous or conjunctival administration of tetanus toxoid (TTd), a model antigen.
Materials and methods: BALB/c and C57BL/6 mice were immunized either subcutaneously with TTd alone or via the
conjunctiva with TTd alone, TTd mixed with 2% glycerol or TTd with merthiolate-inactivated whole-cell B. pertussis (wBP) as
adjuvants. Mice were immunized on days 0, 7 and 14 via both routes, and an evaluation of the local and systemic immune
responses was performed two weeks after the last immunization. Four weeks after the last immunization, the mice were
challenged with a lethal dose (2 6 LD50) of tetanus toxin.
Results: The conjunctival application of TTd in BALB/c mice induced TTd-specific secretory IgA production and skewed the
TTd-specific immune response toward a Th1/Th17 profile, as determined by the stimulation of IFNc and IL-17A secretion
and/or the concurrent pronounced reduction of IL-4 secretion, irrespective of the adjuvant. In conjunctivaly immunized
C57BL/6 mice, only TTd administered with wBP promoted the establishment of a mixed Th1/Th17 TTd-specific immune
response, whereas TTd alone or TTd in conjunction with glycerol initiated a dominant Th1 response against TTd.
Immunization via the conjunctiva with TTd plus wBP adjuvant resulted in a 33% survival rate of challenged mice compared
to a 0% survival rate in non-immunized animals (p,0.05).
Conclusion: Conjunctival immunization with TTd alone or with various adjuvants induced TTd-specific local and systemic
immune responses, predominantly of the Th1 type. The strongest immune responses developed in mice that received TTd
together with wBP, which implies that this alternative route might tailor the immune response to fight intracellular bacteria
or viruses more effectively.
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Introduction
The conjunctiva, which lines the ocular surface from the corneal
rim to the lid margin [1], and its underlying structures are now
recognized as a part of the mucosa-associated lymphoid tissue
(MALT), annotated as conjunctiva-associated lymphoid tissue
(CALT) or eye-associated lymphoid tissue (EALT) [2]. CALT has
the typical components of a physiologically protective mucosal
immune system, as it contains diffuse lymphoid tissues and
lymphoid follicles that form the efferent and afferent limbs,
respectively, of lymphoid tissue. Thus, CALT can detect antigens
from the ocular surface, present the antigens and generate
protective effector cells; together, these properties signify the
presence of a mucosal immune system at the conjunctiva [3], [4],
[5], [6]. Theoretically, the conjunctiva is an attractive choice for
mucosal immunization, particularly against ocular infections, as
eye drops are easily administered; drop-count dosing is feasible;
and as the conjunctiva is interconnected with the nasal mucosa via
the tear ducts, the administration of antigens to the conjunctival
sac would additionally drain to the nasal-associated lymphoid
tissue (NALT). Nevertheless, the conjunctival route has been
exploited predominately only in veterinary applications in the use
of live attenuated vaccines, which have proven to be efficient
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against various infectious diseases [7], [8]. Several vaccines that
use this strategy have been licensed, including poultry vaccines
against Newcastle virus, infectious bursitis virus, chicken herpes virus
and turkey herpes virus; feline vaccines against viral rhinotrache-
itis, calicivirus and panleukopenia; and goat and sheep vaccines
against Brucella melitensis [9], [10], [11], [12], [13].
For human use, live attenuated vaccines have certain limita-
tions: there is a possibility that an attenuated microbe in a vaccine
could revert to a virulent form and cause disease, subjects who
have damaged or weakened immune systems cannot safely receive
the vaccines, and the vaccines often require refrigeration to remain
viable [14]. In contrast, subunit vaccines, which are based on
purified protective proteins or carbohydrates, might be a safe
alternative to live attenuated vaccines [15]. However, little is
known about the conjunctival immunization and its immune
response profile concerning protein subunit vaccines, particularly
compared to systemic vaccination. Previous comparative studies
on conjunctival immunization have been performed, albeit with
certain constraints: 1) two different effects were compared, e.g.,
immune responses elicited with a live attenuated vaccine
administered subcutaneously were compared to responses elicited
with a subunit vaccine applied via the conjunctiva [16]; 2) immune
responses after conjunctival immunization with either live
attenuated vaccines or peptides were assessed without comparison
to systemic routes [17], [18], [19]; 3) in lieu of an immune
response, anergy was induced following the administration of
different doses of ovalbumin twice per day for 10 days via the
conjunctiva following the subcutaneous administration of Ag [20].
Consequently, an immune response profile of the mucosal/
conjunctival route versus the parenteral/subcutaneous route of
immunization using protein subunits in combination with suitable
ocular adjuvants is currently absent. Therefore, the aim of our
study is first to undertake a comparative study of the local and
systemic immune responses after conjunctival and subcutaneous
immunizations using TTd as a model antigen. The overall
rationale for choosing TTd was that this antigen has previously
been used as a valuable model antigen [21], and TTd is well
known as a strong immunogen [22]. Furthermore, as TTd is an
active component of the vaccine against tetanus, the immune
response obtained via subcutaneous immunization with TTd is
well characterized and can be used as a ‘‘gold standard.’’
Second, because many ocular surface pathogens are either
intracellular bacteria or viruses that require a (Th1) for clearance,
we further assessed the influence of Th1-promoting adjuvants,
applied together with the antigen, on the immune response
induced by conjunctival immunization while ensuring that the
choice of adjuvant was tolerated by the ocular surface.
Third, we used two genetically different inbred mouse strains,
BALB/c and C57BL/6 (with predominantly Th2 and Th1
immune responses, respectively), to gain a broader understanding
of the immune response elicited by conjunctival immunization.
Materials and Methods
Mice
Eight-week-old BALB/c and C57BL/6 female mice were used
in the experiments. All experiments were approved by the ‘‘Ethics
Committee for the Welfare of Experimental Animals’’ and by the
committee section at the Institute of Virology, Vaccines and Sera –
Torlak and conformed to the Serbian laws and European
regulations on animal welfare (Approval No. 011-00-00510/
2011-05/2).
Antigens, Adjuvants and Immunization and Bleeding
Schedules
BALB/c and C57BL/6 female mice were immunized via the
conjunctiva (conj//) with TTd (Institute of Virology, Vaccines and
Sera – Torlak, Belgrade, Serbia) as a model antigen (100 mg TTd/
PBS per mouse in 10 ml (5 ml per eye) was applied to the
conjunctiva), and 2% glycerol (glyc) and merthiolat-inactivated
whole cell B. pertussis (wBP) (Institute of Virology, Vaccines and
Sera – Torlak, Belgrade, Serbia) were used as Th1-promoting
adjuvants. These adjuvants were chosen because glyc is commonly
used in eye drops for human use at this concentration and because
preliminary experiments in which wBP was administered in a
corpusculated form or as an adjuvant platform revealed no visible
signs of inflammation or infection at the ocular surface. Mice
(n = 10 per group) were immunized on days 0, 7 and 14 via either
the conj//or sc//routes, and the evaluations of local and systemic
immune responses were conducted two weeks after the last
immunization. According to the applied immunization protocols,
the mice were divided into the following four experimental groups:
conj//TTd, conj//TTd/glyc, conj//TTd/wBP and sc//TTd.
Age-matched, non-immunized mice and conj//glyc- and conj//
wBP-treated mice were used as controls.
All vaccines were prepared in situ by mixing defined volumes of
the stock TTd and wBPsolutions (both in PBS) or concentrated
glycerol (stock solution 85%) in order to prepare vaccines that
finally contain:
– 10 mg/ml TTd in PBS for conj//TTd
– 10 mg/ml TTd and 2% glycerol in PBS for conj//TTd/glyc
– 10 mg/ml TTd and 26108 cells/ml wBP in PBS for conj//
TTd/wBP
– 1 mg/ml TTd in PBS for sc//TTd
– 2% glycerol in PBS for conj//glyc
– 26108 cells/ml wBP in PBS for conj//wBP
Obtained solutions were mixed thoroughly by vortexing for 30
minutes and 5 ml per eye (in total 10 ml per mice) were applied via
conjunctiva. 100 ml per mouse was applied subcutaneously.
Mice that were immunized via the conjunctiva were anaesthe-
tized by intraperitoneal (i.p.) administration of a mixture of
xylazine (Sigma-Aldrich, Kansas, KS, USA) and ketamine
(Richter Pharma AG, Wels, Austria). Antigens were applied onto
the conjunctival sacs using a micropipette. The mice were
maintained under anesthesia for 30 minutes to prevent removal
of the immunization solution.
Subcutaneously immunized (sc//) mice were used as a ‘‘gold
standard’’ (100 mg TTd/PBS per mouse in 100 ml). The TTd used
for the immunizations met the standards for specific and reversed
toxicity according to the European Pharmacopoeia requirements.
Sample Collection
Samples of blood sera were collected by bleeding from the retro-
orbital sinuses two weeks after the completion of the immunization
protocol. The collected sera were complement depleted, aliquoted
and stored at –20uC. Tear-wash samples were obtained by lavage
with 10 ml PBS per eye. The collected tears were supplemented
with a protease inhibitor cocktail (Thermo Scientific, USA) and
stored at –80uC.
Detection of TTd-specific IgG, IgG Subclasses and IgA in
Mouse Sera and Tears
ELISA plates (MaxiSorp; Nunc, Roskilde, Denmark) were
coated (50 ml/well) with TTd (2.5 mg/ml TTd in PBS) by
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overnight adsorption at 4uC, and 1% (w/v) BSA/PBS was
applied as a blocking reagent for 2 h at room temperature. This
blocking step, as well as all subsequent ELISA steps, was
followed by a wash with 0.05% (v/v) Tween 20 in PBS (four
times, 200 ml/well). Appropriately diluted non-pooled serum
(1:100) and tear (1:2) samples were incubated in the plates for
1 h at room temperature. Ag-specific antibody binding was
detected with after 1 h incubation at room temperature using
biotin-labeled anti-mouse IgG (Sigma, Steinheim, Germany),
biotin-labeled anti-mouse IgG1, IgG2a, and IgG2c antibodies
(Sigma, Steinheim, Germany) and biotin-labeled anti-mouse IgA
antibody (BioLegend). Antigen-antibody interactions were visu-
alized using the extrAvidin-peroxidase/o-phenylendiamine sys-
tem (Sigma, Steinheim, Germany), and absorbance was
recorded at 492/620 nm (A492/620). The cutoff value for each
system was defined according to the A492/620 value obtained
from ‘‘negative control’’ wells (1% BSA w/v in PBS as a
sample) plus 36SD. Samples were considered positive when the
A492/620 value exceeded the cutoff value.
Cells from Draining Lymph Nodes
Submandibular (SMLN) lymph nodes from mice that were
immunized via the conjunctiva and from control mice were
aseptically isolated, trimmed of all excess tissue and placed in
sterile complete RPMI 1640 (Sigma-Aldrich) supplemented with
inactivated 5% fetal calf serum (FCS). Lymphocytes were
harvested in 5% FCS/RPMI 1640 and passed through sterile
steel mesh to remove large particles. Cell suspensions were
centrifuged at 1000 rpm (SIGMA 3K18, Sigma Laboratory
Centrifuges GmbH) to yield pellets. After centrifugation, the
lymphocytes were washed three times in 5% FCS/RPMI 1640
with centrifugation at 1000 rpm (5 min). The cells were finally
diluted in 10% FCS/50 mM b-mercaptoethanol/RPMI 1640 to a
concentration of 26106 cells/ml. The viability of these cell
preparations, as determined by trypan blue exclusion, was greater
than 95%. Lymphocytes (26106 cells/ml) were used for ELISA or
were stimulated in vitro (37uC, 5% CO2, 48 h). As a stimulus, TTd
was added to the cultures at 5 mg/ml.
Abundance of TTd-specific B cells within the Total mIgG+
B cell Population in Draining Lymph Nodes
The abundance of the specific B cell population was investigated
using an ELISA-based procedure. SMLN suspensions were
simultaneously assessed for both the amount of total mIgG+ cells
as well as TTd-specific mIgG+ B cells. All washes were conducted
in PBS. For the detection of total mIgG+ B cells, MaxiSorp
microtiter plates (Nunc) were coated (50 ml/well, overnight at 4uC)
with commercially available polyclonal anti-mouse IgG (10 mg/ml
PBS; Sigma M 0659). Suspensions containing 26105 cells/ml were
added to the blocked (1% BSA in PBS) anti-mouse IgG-coated
wells (50 ml/well) to assess the total number of mIgG+ B cells. The
coating procedure that was previously described in the Materials
and Methods section (for the detection of IgG and IgA specific for
TTd in the sera and tears) was applied for the detection of TTd-
specific B cells. For this assessment, suspensions containing 26106
cells/ml were used (50 ml/well). TTd-specific and total mIgG+ B
cells were detected using polyclonal alkaline phosphatase-labeled
anti-mouse IgG (Sigma, A-3562). Non-specific binding was
assessed in wells that were blocked but were not coated with
reagents (i.e., those lacking capture antibody and specific antigen).
The amount of bound alkaline phosphatase-labeled antibodies per
well was evaluated using p-nitrophenyl phosphate as a substrate.
The transformation of p-nitrophenyl phosphate by alkaline
phosphate occurred at the same rate in all wells. The abundance
of specific B cells within the mIgG+ population was calculated for
each individual animal. Using the A405 value measured upon the
evaluation of total mIgG-expressing cells (A405tot) and the
corresponding A405 value measured upon specific B cell assess-
ment (A405spec), the relative abundance (RA) of specific B cells was
calculated as follows: RA = (A405spec6100)/A405tot.
MTT Assay
Following 48 h of incubation (5% CO2, 37uC), the plates
containing the cell cultures were centrifuged (800 rpm, 10 min),
and the supernatants were decanted. DMEM/25 mM HEPES/
0.2% NaHCO3 containing 500 mg/ml of 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma-Aldrich) was
added to the experimental wells (100 ml/well), and the cells were
incubated (37uC, 5% CO2, 4 h). Reactions were halted by the
addition of 10% SDS/10 mM HCl (100 ml/well). After an
overnight incubation at 37uC, absorbance values were measured
at 580 nm (A580) using a spectrophotometer (Ascent 6–384
[Suomi], MTX Lab Systems Inc., Vienna, VA, USA). The
number of viable cells per well (NVC) was calculated from a
standard curve drawn as the number of cells plotted against A580.
Standard curves were drawn for both mouse strains (BALB/c and
C57BL/6). Discrete pools of non-stimulated cells were taken from
each strain and, after counting the cells using a hemocytometer,
were then used as standards. Standard suspensions were plated in
serial dilutions prior to centrifugation and were then were treated
identically to the experimental wells that received stimulated
aliquots. A proliferation index (PI) for each stimulated cell
suspension was calculated per individual source animal. The PI
index was defined as the ratio of NVC present in stimulated (S)
samples to NVC present in non-stimulated (nS) samples, such that
PI = NVCS : NVCnS.
Cytokine Profile of Draining Lymph Node Cells
The production of IFNc, IL-4, IL-17A and IL-10 was analyzed
by measuring the supernatant concentrations of non-stimulated
and TTd-stimulated SMLN lymph node cultures using sandwich
ELISAs with commercially available monoclonal antibodies
(eBioscience). Unlabeled monoclonal Abs specific for IFNc
(1 mg/ml), IL-4 (2 mg/ml), IL-17A (1 mg/ml) or IL-10 (1 mg/ml)
were coated onto microtiter plates (MaxiSorp, Nunc) by overnight
adsorption at 4uC, and 1% BSA/PBS (w/v) was used to block the
plates (2 h) at room temperature. Blocking and all subsequent
ELISA steps were followed by a wash step with 0.05% (v/v)
Tween 20 in PBS (four times, 200 ml/well). Lymph node
supernatants were incubated in the plates (1 h) at room
temperature. Biotin-labeled Abs specific for IFNc (2 mg/ml), IL-
4 (1 mg/ml), IL-17A (1 mg/ml) or IL-10 (1 mg/ml) and formulated
in 1% BSA/PBS (w/v) were then added to the wells and incubated
for 1 h at room temperature. The extrAvidin-alkaline phospha-
tase/p-nitrophenyl phosphate system (Sigma-Aldrich) was used to
visualize antigen–Ab interactions. Absorbance was monitored at
405 nm (A405). The cutoff value for each system was calculated as
the displayed A405 reading measured in the negative control well
(1% BSA/PBS used as a sample) plus 36SD. Standard curves
were created using commercially available recombinant mouse
IFNc, IL-4, IL-17A and IL-10.
Protection Assay Against Tetanus Toxin (TTn)
Four weeks after the course of conj//and sc//immunizations,
anesthetized mice (n = 6) were challenged with a lethal dose
(26LD50) of TTn by intraperitoneal (i.p.) injection. The animals
were monitored for weight loss and survival every day for 5 days.
The Conjunctiva as a Mucosal Immunization Route
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Tolerability at the Ocular Surface
Signs of ocular irritation were monitored in BALB/c and
C57BL/6 mice immunized via the conjunctiva and in non-
immunized controls daily during the course of immunization and
every week for the remainder of the study by two unbiased
observers. Conjunctival hyperemia, edema and corneal clarity
were assessed using magnifying loupes.
Statistical Analysis
The results are presented as the mean values 6 standard error
(SE). The statistical significance of the observed differences was
evaluated using the t-test for independent groups. A probability (P)
value of 0.05 was set as the limit of significance (software:
ORIGIN 8.0). The correlation between variables was evaluated by
Pearson’s bivariate correlation analysis (software: IBM SPSS
Statistics 20).
Results
Secretory IgA (SIgA) Levels in Tears Increased in Both
Mouse Strains Following TTd Immunization via the
Conjunctiva versus Subcutaneous Immunization
Immunization through the conjunctival route resulted in levels
of TTd-specific SIgA in both mouse strains that were significantly
higher than those found in the tears of syngeneic control mice
(non-immunized and adjuvant-alone immunized) as well as mice
that were subcutaneously immunized with TTd (Fig. 1). The
amount of TTd-specific SIgA detected in the tears of sc//TTd-
immunized mice was negligible and was similar to the levels found
in tears from non-immunized mice. Although the mean levels of
SIgA in the tears of conj//TTd/wBP-immunized mice were
higher compared to levels in conj//TTd- and conj//TTd/glyc-
immunized mice of the same strain, these differences were not
significant. With regard to the different mouse strains, BALB/c
mice exhibited greater SIgA concentrations in tears than C57BL/
6 mice, although this difference was not significant.
Serum IgG and IgA Levels Increased Following
Conjunctival Immunization with TTd when wBP was used
as an Adjuvant
In both mouse strains, conjunctival immunization with TTd,
TTd/glyc or TTd/wBP resulted in significantly higher levels of
TTd-specific IgG (Fig. 2a) and IgA (Fig. 2b) in the serum
compared to serum from non-immunized or adjuvant-alone-
immunized mice.
Generally, anti-TTd IgG and IgA levels in the serum of
conjunctively immunized BALB/c mice were higher than the
levels in the serum of C57BL/6 mice treated the same way. A
comparison of the syngeneic mice immunized with TTd via the
conjunctiva revealed that, except in the case of anti-TTdIgG in
BALB/c mice, there were no significant differences in the levels of
sera anti-TTd antibodies among the mice. The conjunctival
administration of TTd mixed with wBP promoted a significantly
higher (P,0.05) systemic production of TTd-specific IgG than the
administration of TTd alone. In comparison to the ‘‘gold
standard’’ (sc//immunization with TTd without adjuvant), the
levels of serum TTd-specific IgG were significantly lower in all
mice that were immunized with TTd via the conjunctiva
(P,0.0005 in comparison to sc//TTd-immunized mice of the
same strain). Regarding the level of sera TTd-specific IgA, the
conjunctival administration of TTd in BALB/c mice was superior
to subcutaneous administration (P,0.05), whereas in C57BL/6
mice an opposite situation is recorded (P,0.05).
Serum IgG Antibody Subclass Responses Provided the
Initial Evidence that Immunization with TTd via the
Conjunctiva can Induce Skewing of TTd-specific Immune
Responses towards a Th1–type Response
When the TTd-specific serum IgG subclass immune responses
were assessed (Fig. 3), the ratios of IgG1 and IgG2a in BALB/c
mice and IgG1 and IgG2c in C57BL/6 mice were significantly
higher in sc//2immunized mice in comparison to each group of
mice that were immunized via the conjunctiva (P,0.05 for
BALB/c and P,0.0005 for C57BL/6). The rise in the abundance
of IgG antibodies that are dependent on IFNc for secretion (i.e.,
IgG2a in BALB/c and IgG2c in C57BL/6) in the TTd-specific
sera IgG pool of conjunctively immunized mice indicated that Th1
immune response skewing had occurred. Although there were
differences in the IgG1/IgG2a,c ratios among syngeneic conjunc-
tively immunized mice, these differences were not significant.
An Increased Population of TTd-specific B cells within the
Total SMLN B cell Population Strongly Correlated with
Levels of Sera TTd-specific Antibodies
An increased population of TTd-specific B cells was found
within the total mIgG+ B cell population in the draining lymph
nodes of mice immunized with TTd via the conjunctiva (Fig. 4).
Compared to the syngeneic age-matched control group, as well as
groups treated with glyc or wBP alone, a significantly higher
frequency of mIgG+ TTd-specific B cells within the draining
SMLN was evident in all these groups (P,0.05). The greatest
abundance of TTd-specific B cells in mice immunized via the
conjunctiva was found in the TTd/wBP groups (P,0.005 in
comparison to the corresponding n.c.). Bivariate correlation
analyses confirmed a strong correlation between the levels of
TTd-specific IgG in the serum and the relative abundance of
TTd-specific B cells in the draining lymph nodes (P,0.01; for
BALB/c and C57BL/6 mice, the Pearson correlation coefficients
were 0.787 and 0.832, respectively).
The Greatest Proliferation of Draining SMLN Cells in
Response to TTd was Observed using wBP as an
Adjuvant
SMLN cells from immunized mice were used to perform a cell
proliferation assay (Fig. 5). Following immunization via the
conjunctiva, both mouse strains showed almost identical trends
in proliferation index values following stimulation with TTd.
Among the groups that were immunized via the conjunctiva,
SMLN cells from the TTd/wBP group showed the highest
proliferation index values in response to TTd. In C57BL/6 mice,
PIs recorded for the conj//TTd/wBP group were significantly
higher than those for the conj//TTd group.
Immunization with TTd/wBP via CALT Promoted the
Establishment of a Th1 TTd-specific Immune Response
SMLN cells from immunized and non-immunized control
BALB/c and C57BL/6 mice were stimulated in vitro with TTd
and analyzed for the production of IFNc (a marker of Th1
responses), IL-4 (a marker of Th2 responses), IL-17A (a marker of
Th17 responses) and IL-10 (a cytokine with regulatory and anti-
inflammatory roles) (Fig. 6). As shown in Fig. 6, SMLN cells
produced the tested cytokines without any additional stimulation
during in vitro cultivation. Some treatment-dependent differences
in the production of specific cytokines were marked, although the
majority of the differences were not significant (data not shown).
However, in vitro TTd stimulation generally altered the production
The Conjunctiva as a Mucosal Immunization Route
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of the tested cytokines in the SMLN cultures derived from
conjunctively immunized mice.
A conjunctival multi-dose application of TTd alone, without an
adjuvant, in BALB/c mice resulted in the diminished capacity of
draining SMLN cells to produce IFNc (P,0.05 in comparison to
the BALB/c n.c. group) and IL-4 (the concentration was below the
limit of detection) but an enhanced capacity to produce IL-17A
(P,0.05 in comparison to the BALB/c n.c. group) following
Figure 1. Levels of TTd-specific SIgA in tear washes from BALB/c and C57BL/6 mice that were immunized according to the assigned
protocols. Samples were collected two weeks after the completion of the immunizations and were assayed by ELISA (dilution 1:2). The results are
presented as the mean A492/6206 SE (n = 10). The significance of the observed differences was calculated by t-test (P,0.05*, P,0.005**). The reference
group is indicated by a dotted line, and the comparison group is indicated by an arrow.
doi:10.1371/journal.pone.0060682.g001
Figure 2. Levels of TTd-specific IgG (A) and IgA (B) in the sera of BALB/c and C57BL/6 mice immunized according to the assigned
protocols. Serum samples were collected two weeks after the completion of the immunizations and were assayed by ELISA (dilution 1:100). The
results are presented as the mean A492/6206 SE (n = 10). The significance of the observed differences was calculated by t-test (P,0.05*, P,0.005**,
P,0.0005***, P,0.00005). The reference group is indicated by a dotted line, and the comparison group is indicated by an arrow.
doi:10.1371/journal.pone.0060682.g002
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in vitro TTd stimulation. In C57BL/6 mice treated in an identical
manner, TTd stimulation of SMLN cells induced IL-10 secretion
(P,0.005 in comparison with the C57BL/6 n.c. group), whereas
the production of IFNc, IL-17A and IL-4 was not affected in
comparison to non-immunized mice.
Conj//TTd/glyc immunization caused a reduction in the
capacity of SMLN cells from BALB/c mice to secrete IFNc and
IL-4 (P,0.005 in comparison to the n.c. group) upon TTd
stimulation. In these cultures, only the secretion of IL-17A was
augmented (P,0.005 in comparison to the n.c. group). In contrast,
SMLN cells from conj//TTd/glyc-immunized C57BL/6 mice
produced IFNc (P,0.05) and IL-4 (P,0.005) in higher quantities
upon in vitro TTd stimulation than did the SMLN cells from
control mice, whereas the production of IL-17A was similar to that
detected in SMLN cultures from non-treated mice.
Significantly higher levels of both IFNc (P,0.005 for BALB/c,
P,0.05 for C57BL/6) and IL-17A (P,0.005 for both strains)
upon in vitro TTd stimulation were detected in SMLN cell cultures
obtained from conj//TTd/wBP-treated mice compared to the
corresponding TTd-stimulated control cell cultures obtained from
non-immunized mice. The increased production of IFNc upon
TTd stimulation was also observed in cultures from conj//wBP-
immunized mice (for both mouse strains, P,0.05 in comparison to
the corresponding n.c. group), whereas the production of IL-17A
was not significantly greater than that observed in corresponding
non-stimulated cultures. In TTd-stimulated cultures of SMLN
cells from conj//TTd/wBP BALB/c mice, IL-10 production was
also stimulated (P,0.05) in addition to in IFNc and IL-17A
production, whereas IL-4 production was diminished (P,0.005) in
comparison to a reference culture of non-treated murine lymph
node cells. In C57BL/6 mice, TTd stimulation did not affect the
secretion of IL-4 by cells from conj//TTd/wBP lymph nodes but
augmented the production of IL-10 (P,0.005 in comparison to
the n.c. group).
Conjunctival Immunization with TTd Mixed with wBP
Partially Protects BALB/c and C57BL/6 Mice Against
Lethal Challenge with TTn
Treatment-dependent survival upon challenge with a lethal dose
of TTn was similar in both mouse strains. All subcutaneously
immunized mice survived challenge with a lethal dose of TTn. All
non-immunized mice, as well as mice conjunctively immunized
with TTd alone, TTd/glyc, glyc or wBP, died on the first day
post-challenge. Among the conjunctively immunized mice of both
strains, only 33.3% of mice immunized with TTd/wBP survived
the TTn challenge. It is evident that the survival rate of conj//
TTd/wBP-immunized mice was lower than that of subcutane-
ously immunized mice (P = 0.0001) but was significantly greater
than that of the non-treated age-matched control group and other
groups treated via the conjunctiva (P = 0.028). The survival of sc//
TTd- and conj//TTd/wBP-immunized mice, as well as age-
matched control mice, upon challenge with a lethal dose of TTn is
depicted in Fig. 7. Bivariate correlation analyses showed that the
survival rates of both mouse strains upon challenge with TTn
positively correlate to the level of sera anti-TTd IgG (P,0.01; for
Figure 3. IgG1/IgG2a (A) and IgG1/IgG2c (B) ratios calculated for TTd-specific antibodies in the sera of TTd-immunized BALB/c and
C57BL/6 mice, respectively. Serum samples were collected two weeks after the completion of the immunizations and were assayed by ELISA
(dilution 1:100). Ratios were determined using the A405 values obtained upon the measurement of TTd-specific IgG1 and IgG2a or IgG2c in sera. The
results are presented as the mean A405(IgG1)/A405(IgG2a,c) 6 SE (n = 10). The significance of the differences between syngeneic mice immunized
subcutaneously with TTd (reference group) and those immunized via the conjunctiva was calculated by t-test (P,0.05*, P,0.005**, P,0.0005***).
doi:10.1371/journal.pone.0060682.g003
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BALB/c and C57BL/6 mice, Pearson correlation coefficients were
0.817 and 0.511, respectively).
No Ocular Irritation or Pathology was Observed at the
Ocular Surface of Conjunctively Immunized Mice
Non-biased observers did not detect any signs of inflammation
at the ocular surfaces of either mouse strain following immuniza-
tion via the conjunctiva, as the eyes of non-immunized and sc//
2immunized mice were visually identical to those of mice
immunized via the conjunctiva. In addition, all mice remained
healthy until the time of sacrifice, as there were no observed
behavioral changes or weight loss during the course of immuni-
zation.
Discussion
The delivery of antigens through mucosal surfaces is of
remarkable interest because this route (i) mimics bacterial infection
patterns and (ii) generates immunity at the major port of entry for
such microorganisms [23]. Conjunctival immunization is an
alternative approach to needle-based vaccine delivery against
both mucosal (in particular, ocular) and systemic diseases, and
more extensive research is needed to fully characterize the nature
of the immune response stimulated by this route. It is likely that
the response will vary for different antigens and will depend on
whether adjuvants are required to enhance the specific response.
In this study, we evaluated characteristics of the conjunctival
mucosal immunization route in profiling and comparing the local
and systemic immune responses to the subcutaneous route using
TTd as a model antigen. Here, we showed that immunization with
TTd via the conjunctiva induced TTd-specific SIgA immune
responses at the ocular surfaces in addition to the production of
specific IgG and IgA antibodies detected in the serum. In both
mouse strains, the SIgA concentrations in tears were higher in
mice that were immunized via the conjunctiva than in mice that
were sc//immunized, which is in agreement with previous
publications using live attenuated vaccines [24], [25], [26]. The
induction of B cell responses by conjunctival immunization was
further supported by the presence of large numbers of mIgG+
TTd-specific cells within the SMLN total B cell population in all
experimental groups. These data revealed that the levels of TTd-
specific antibodies in murine sera induced by conjunctival
administration of TTd strongly correlated with the presence of
TTd-specific B cells in the draining lymph nodes. In all
immunized groups of mice, the levels of TTd-specific antibodies
in both tears and serum were higher in BALB/c mice than in
C57BL/6 mice, which may be explained by the different genetic
backgrounds of these mice.C57BL/6and BALB/c mice are examples of
mouse strains with predominantly Th-1 and Th2-type immune
responses, respectively, both in vivo and in vitro. It is generally
accepted that differences in the responses to pathogens by these
two strains result from differences in the capacities for Th cell
polarization, as BALB/c mice are genetically predisposed to
Figure 4. The relative abundance (RA) of TTd-specific mIgG+ B cells within the total population of mIgG+ B cells in SMLN upon
completion of the assigned immunization protocols. The RA of the TTd-specific mIgG+ B cell population was calculated for each mouse. The
results are presented as the mean RA 6 SE for each experimental group of mice (n = 5). The statistical significance of the observed differences in TTd-
specific mIgG+ B cell pool abundances was determined by t-test (P,0.05*, P,0.005**, P,0.0005***). The reference group is indicated by a dotted line,
and an arrow indicates the comparison group.
doi:10.1371/journal.pone.0060682.g004
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establish a dominant Th2 immune response that is characterized,
among other phenotypes, by cytokine production that promotes a
humoral immune response.
As the most important finding, we demonstrated that the route
of immunization highly influenced differentiation toward a Th1 or
Th2 immune response. It is well known that subcutaneously
administered TTd induces a Th2 immune response [27], [28],
which is necessary for protection against tetanus. An analysis of
cytokine secretion in draining SMLN cells upon in vitro stimulation
with TTd revealed that immunization with TTd via the
conjunctiva induced the skewing of TTd-specific immune
responses toward a Th1-type response in both mouse strains,
irrespective of the accompanying adjuvant, as determined by the
stimulation of IFNc secretion and/or diminished IL-4 production.
Furthermore, this finding was supported by the prominent
secretion of IFNc-dependent antibody subclasses (IgG2a and
IgG2c in BALB/c and C57BL/6 mice, respectively), which also
indicate Th1-type immunity.
It is well known that an adjuvant is vital in inducing a strong
immune response to the co-administered subunit antigen. Our use
of wBP as an adjuvant was the best promoter of protective TTd-
specific antibody secretion and profoundly modulated cytokine
secretion. The characteristics of the immune responses observed in
both mice strains upon immunization via the conjunctiva with
wBP-adjuvanted TTd supported previous data showing that Th2
tetanus-specific immune responses are modified to a mixed Th1/
Th2 response when TTd is co-injected with wBP cells [29]; thus,
the whole-cell B. pertussis vaccine has the potential to suppress Th2-
associated humoral responses to antigens if the antigen and
adjuvant are administered simultaneously [30], and inactivated B.
pertussis can promote the differentiation of Th1, as well as Th17,
cells [31], [32]. Independent of the mouse strain used, conj//
TTd/wBP immunization initiated mixed Th1/Th17 TTd-specific
immune responses. Furthermore, mixed Th1/Th17 responses
were initiated only when wBP was used as an adjuvant; in BALB/c
mice, the conjunctival application of TTd alone or TTd
adjuvanted with glyc impaired IFNc secretion, and Th17
differentiation was impaired in similarly treated C57BL/6 mice.
The induction of mixed Th1/Th17 immune responses may be
crucial for defenses against intracellular parasites, as IFNc and IL-
17 synergistically enhance the resolution of such infections [33].
The results obtained from our model system are in line with a
growing body of data that collectively imply that proper
stimulation through TLRs is of immense importance for the
establishment of protective immune responses. Furthermore,
increases in the production of the pro-inflammatory cytokines
IFNc and IL-17 in most groups was accompanied by enhanced IL-
10 secretion, which was most likely produced to counterbalance
Figure 5. The proliferation indices (PI) of TTd-stimulated SMLN cells from BALB/c and C57BL/6 mice immunized via the conjunctiva
according to the assigned immunization protocol. The numbers of viable SMLN cells were assessed by MTT assay following a 48 h cultivation
in 10% FCS/50 mM b-mercaptoethanol/RPMI 1640 medium supplemented or not with TTd (5 mg/ml). PIs were calculated for each mouse. The results
are presented as the mean PI 6 SE for each experimental group (n = 10). The statistical significance of the differences in PIs between groups treated
according to the assigned protocols was determined by t-test (P,0.05*, P,0.005**). The reference group is indicated by a dotted line, and the
comparison group is indicated by an arrow.
doi:10.1371/journal.pone.0060682.g005
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the pro-inflammatory responses. In addition to its pivotal role in
Th17 skewing, TLR4 signaling in innate immune cells activates
innate IL-10 production in response to wBP [30]. Therefore, we
believe that this occurrence may explain the observed increases in
IL-10 production in mice of both strains when wBP was used as an
adjuvant. We propose that in our system, IL-10 acted primarily as
an anti-inflammatory agent to balance IFNc and IL-17 secretion,
thus exerting a beneficial effect. It is likely that wBP limited
inflammatory pathology by promoting the induction of IL-10-
secreting type 1 regulatory T cells.
Although our aim and immunization protocol were not
primarily targeting systemic protection, as most ocular surface
diseases are localized, we obtained partial systemic protection in
both mouse strains upon challenge with a lethal dose of TTn. In
our model system, we induced primarily a Th1/Th17 response
following immunization via the conjunctiva, whereas Th2-type
responses obtained by sc//immunization have been shown to be
important for full protection against tetanus [34], namely,
neutralizing tetanus-specific antibodies are key factors for protec-
tion against tetanus. The secretion of these antibodies is greater in
a Th2-type immune response, although skewing of the immune
response toward Th1 does not completely block the production of
such antibodies; in this case, antibody secretion occurs but is not
dominant in the overall immune response.
Figure 6. Levels of IFNc (A), IL-4 (B), IL-17A (C) and IL-10 (D) in the supernatants from in vitro TTd-stimulated SMLN cells obtained
from age-matched control mice (n.c.) and mice immunized via the conjunctiva according to the assigned protocol (bars). SMLN cells
were cultivated at 37uC in 5% CO2 for 48 h in 10% FCS/RPMI 1640/50 mM b-mercaptoethanol supplemented with 5 mg/ml TTd. The levels of cytokines
in the supernatants of corresponding SMLN cells incubated in 10% FCS/RPMI 1640/50 mM b-mercaptoethanol under similar conditions (non-
stimulated cells) are indicated by solid lines. The results are presented as the mean concentration 6 SE (n = 10). Concentrations of cytokines in
supernatants of TTd-stimulated cultures were compared by t-tests. The reference group is indicated by a dotted line, and the comparison group is
indicated by an arrow. A t-test was also used for the comparison of cytokine concentration in supernatants of corresponding non-stimulated and TTd-
stimulated cultures, and the statistical significance of the differences is marked next to the solid bar, indicating the level of the cytokine within the
non-stimulated culture. The levels of statistical significance are assigned as follows: P,0.05*, P,0.005**, P,0.0005***.
doi:10.1371/journal.pone.0060682.g006
The Conjunctiva as a Mucosal Immunization Route
PLOS ONE | www.plosone.org 9 April 2013 | Volume 8 | Issue 4 | e60682
By varying the TTd concentration, immunization scheme and
design of delivery (e.g., not only simple mixing but also some
coupling) in our model system, enhanced systemic protection
against TTn in mice immunized via the conjunctiva will surely
be achievable. However, the aim of this study was not to obtain
a vaccine against TTn that could be applied via the conjunctiva
but to use TTd as a model antigen to compare the immune
profile of conjunctival immunization to a well-known and
characterized immunization protocol to discern the features of
conjunctival immunization and to determine whether this route
of immunization could be used to protect against ocular
infections.
Most vaccines are licensed for parenteral administration and fail
to elicit appropriate mucosal immunity needed for protection
against microorganisms that utilize mucosal ports of entry [35].
Consequently, effective conjunctival mucosal vaccines are needed,
as they have the potential to dramatically contribute to the
improvement of global eye health by stimulating protective
immune responses at the site of infection.
We showed that the profile of the immune responses induced
by the conjunctival mucosal route confers to the aforementioned
advantages over parenteral vaccination. First, the most effective
means of inducing an immune response at a specific effectors’
site is localized stimulation or, at the least, stimulation at a
related site in terms of lymph drainage. Second, local exposure
to an antigen resulted in much higher levels of specific SIgA in
the region of exposure. Third, in addition to IgA responses,
conjunctival vaccination induced systemic IgG responses, which
represent a further defense against invasion by microorganisms
or their products. Fourth, in addition to serum IgG and
mucosal IgA antibodies, mucosal immunization stimulated cell-
mediated responses, the latter being important in combating
intracellular pathogens. In addition, conjunctival vaccination
can also be safer and easier to dispense than traditional
(parenteral) vaccines.
These results extend and support those of other authors showing
that immunization via mucosal surfaces offers advantages over
systemic delivery routes in protecting against intracellular patho-
gens. As conjunctival vaccines will be suitable for use in areas
without appropriate health infrastructures, such vaccines have the
potential to be successfully implemented in developing areas where
access to medical personnel is limited and cooling chains are
difficult to maintain. Therefore, the prevention of sight-threaten-
ing diseases might have a socioeconomic impact not only on a
European level but also on a global level.
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Figure 7. Survival rate of BALB/c and C57BL/6 mice immunized with TTd subcutaneously (s.c.//TTd), TTd mixed with wBP via the
conjunctiva (conj//TTd/wBP) and non-treated age-matched mice (n.c.) upon challenge with tetanus toxin (TTn). Mice were immunized
on days 0, 7 and 14 (100 mg TTd per dose) and four weeks after the completion of the specified immunization protocol, mice were challenged by i.p.
administration of 26LD50 of TTn. In both strains, survival rates were the same; hence, a representative plot is provided. Survival rates were monitored
daily. The statistical significance of the differences in survival rates between conj//TTd/wBP (reference group) and s.c.//TTd or n.c. groups was
determined by t-test (P,0.05*, P,0.005**, P,0.0005***). The results are representative of two independent experiments, each comprising 6 mice per
group.
doi:10.1371/journal.pone.0060682.g007
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